Arrowhead Pharmaceuticals 8-K Report: Key Insights & Updates

From the provided section of the financial report, here are the key pieces of information extracted:

Entity Information:

Company Name: Arrowhead Pharmaceuticals, Inc.
CIK (Central Index Key): 0000879407
State of Incorporation: Delaware (DE)
SEC File Number: 001-38042
EIN (Employer Identification Number): 46-0408024
Address: 177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105
Phone Number: 626-304-3400

Filing Information:

Filing Type: 8-K
Filing Date: February 10, 2025

Stock Information:

Common Stock: Par value $0.001 per share
Ticker Symbol: ARWR
Stock Exchange: NASDAQ

Reporting Period:

Start Date: November 26, 2024
End Date: November 26, 2024

Insights:

The filing is a Form 8-K, which is typically used to report major events that shareholders should know about. The specific nature of the event is not detailed in this section but can be critical for stakeholders.
Arrowhead Pharmaceuticals is actively listed on NASDAQ, suggesting it is a public company engaged in pharmaceutical development, which may be of interest to investors and analysts monitoring biotech stocks.
The report covers a single day, indicating that it may relate to a specific event or announcement that occurred on that date.
All relevant identifiers and jurisdictional information are present, ensuring compliance with SEC requirements for reporting.

This analysis provides a snapshot of Arrowhead Pharmaceuticals as of the reporting date, useful for investors, analysts, and stakeholders assessing the company's current status and activity.